SG11201906819VA - Ethane-sulfonate salt of quinoline derivative - Google Patents
Ethane-sulfonate salt of quinoline derivativeInfo
- Publication number
- SG11201906819VA SG11201906819VA SG11201906819VA SG11201906819VA SG11201906819VA SG 11201906819V A SG11201906819V A SG 11201906819VA SG 11201906819V A SG11201906819V A SG 11201906819VA SG 11201906819V A SG11201906819V A SG 11201906819VA SG 11201906819V A SG11201906819V A SG 11201906819VA
- Authority
- SG
- Singapore
- Prior art keywords
- ethane
- sulfonate salt
- quinoline derivative
- quinolinypoxy
- axl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
The present invention relates to N- {5-[(6,7-dimethoxy-4-quinolinypoxy]-2-pyridinyl 1 -2,5 -dioxo- 1 -phenyl- 1 ,2,5,6,7,8-hexahy dro-3-quinolinecarboxamide ethanesulfonate, which has an Axl-inhibiting activity and is 5 useful as an agent for preventing and/or treating immune diseases, cancer, and the like, a crystal thereof, and a pharmaceutical composition thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017011835 | 2017-01-26 | ||
PCT/JP2018/002250 WO2018139527A1 (en) | 2017-01-26 | 2018-01-25 | Ethane-sulfonate salt of quinoline derivative |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201906819VA true SG11201906819VA (en) | 2019-08-27 |
Family
ID=62979439
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201906819VA SG11201906819VA (en) | 2017-01-26 | 2018-01-25 | Ethane-sulfonate salt of quinoline derivative |
Country Status (21)
Country | Link |
---|---|
US (1) | US10836747B2 (en) |
EP (1) | EP3575293B1 (en) |
JP (1) | JP6605763B2 (en) |
KR (1) | KR102571911B1 (en) |
CN (1) | CN110225908A (en) |
AU (1) | AU2018211801B2 (en) |
BR (1) | BR112019015352A2 (en) |
CA (1) | CA3051605A1 (en) |
DK (1) | DK3575293T3 (en) |
ES (1) | ES2872923T3 (en) |
HU (1) | HUE054883T2 (en) |
IL (1) | IL268221B (en) |
MX (1) | MX2019008787A (en) |
MY (1) | MY196680A (en) |
PH (1) | PH12019501693A1 (en) |
PL (1) | PL3575293T3 (en) |
PT (1) | PT3575293T (en) |
RU (1) | RU2019123279A (en) |
SG (1) | SG11201906819VA (en) |
TW (1) | TWI779007B (en) |
WO (1) | WO2018139527A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7156287B2 (en) * | 2017-08-23 | 2022-10-19 | 小野薬品工業株式会社 | Cancer therapeutic agent containing an Axl inhibitor as an active ingredient |
JP7223998B2 (en) | 2017-10-13 | 2023-02-17 | 小野薬品工業株式会社 | Solid cancer therapeutic agent containing an Axl inhibitor as an active ingredient |
CN117624128A (en) * | 2022-08-30 | 2024-03-01 | 药捷安康(南京)科技股份有限公司 | Crystal form of quinoline derivative inhibitor and preparation method and application thereof |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6428234B1 (en) * | 2000-01-07 | 2002-08-06 | Closure Medical Corporation | Adhesive applicator tips with improved flow properties |
CZ20022332A3 (en) * | 2000-01-07 | 2003-01-15 | Transform Pharmaceuticals, Inc. | Sample assembly |
JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Substituted Amid derivatives & methods of use |
WO2007033196A1 (en) | 2005-09-14 | 2007-03-22 | Bristol-Myers Squibb Company | Met kinase inhibitors |
EP2023926B1 (en) | 2006-05-19 | 2011-10-12 | Bayer Pharma Aktiengesellschaft | Pyridonecarboxamide derivatives useful in treating hyper-proliferative and angiogenesis disorders |
CN101528702A (en) | 2006-06-08 | 2009-09-09 | 阿雷生物药品公司 | Quinoline compounds and methods of use |
RU2010146474A (en) | 2008-04-16 | 2012-05-27 | Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. (De) | QUINOLINE DERIVATIVES AS AXL KINAZ INHIBITORS |
UY31800A (en) | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | CANCER TREATMENT METHOD USING A CMET AND AXL INHIBITOR AND AN ERBB INHIBITOR |
WO2009140549A1 (en) | 2008-05-14 | 2009-11-19 | Amgen Inc. | Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer |
CA2738583A1 (en) | 2008-10-01 | 2010-04-08 | Ludwig Institute For Cancer Research | Methods for the treatment of cancer |
JP2010178651A (en) | 2009-02-04 | 2010-08-19 | Eisai R & D Management Co Ltd | Method for detecting action of hgfr inhibitor |
JP5525612B2 (en) | 2010-07-23 | 2014-06-18 | 国立大学法人 東京大学 | Nitrogen-containing heterocyclic derivatives |
JP5791412B2 (en) | 2010-07-26 | 2015-10-07 | 日本碍子株式会社 | Ceramic heater |
EP2423208A1 (en) | 2010-08-28 | 2012-02-29 | Lead Discovery Center GmbH | Pharmaceutically active compounds as Axl inhibitors |
CA2818903C (en) | 2010-12-14 | 2021-03-23 | Electrophoretics Limited | 5-(1,3-benzoxazol-2-yl)-4-(pyridin-4-yl)pyrimidin-2-amine and its use as a casein kinase 1delta inhibitor |
CN102816175B (en) | 2011-06-09 | 2015-12-16 | 上海汇伦生命科技有限公司 | A kind of heterocycle pyridine compounds, its intermediate, preparation method and purposes |
JP2013074633A (en) | 2011-09-26 | 2013-04-22 | Oki Electric Ind Co Ltd | Switching power supply device and automatic teller machine |
HUE033032T2 (en) | 2011-11-14 | 2017-11-28 | Ignyta Inc | Uracil derivatives as axl and c-met kinase inhibitors |
TWI649308B (en) * | 2013-07-24 | 2019-02-01 | 小野藥品工業股份有限公司 | Quinoline derivative |
-
2018
- 2018-01-25 RU RU2019123279A patent/RU2019123279A/en unknown
- 2018-01-25 PT PT187449707T patent/PT3575293T/en unknown
- 2018-01-25 TW TW107102692A patent/TWI779007B/en active
- 2018-01-25 DK DK18744970.7T patent/DK3575293T3/en active
- 2018-01-25 WO PCT/JP2018/002250 patent/WO2018139527A1/en active Application Filing
- 2018-01-25 PL PL18744970T patent/PL3575293T3/en unknown
- 2018-01-25 US US16/480,514 patent/US10836747B2/en active Active
- 2018-01-25 ES ES18744970T patent/ES2872923T3/en active Active
- 2018-01-25 CN CN201880008442.7A patent/CN110225908A/en active Pending
- 2018-01-25 HU HUE18744970A patent/HUE054883T2/en unknown
- 2018-01-25 AU AU2018211801A patent/AU2018211801B2/en active Active
- 2018-01-25 BR BR112019015352-7A patent/BR112019015352A2/en active Search and Examination
- 2018-01-25 CA CA3051605A patent/CA3051605A1/en active Pending
- 2018-01-25 MY MYPI2019004265A patent/MY196680A/en unknown
- 2018-01-25 KR KR1020197021641A patent/KR102571911B1/en active IP Right Grant
- 2018-01-25 SG SG11201906819VA patent/SG11201906819VA/en unknown
- 2018-01-25 JP JP2018564622A patent/JP6605763B2/en active Active
- 2018-01-25 EP EP18744970.7A patent/EP3575293B1/en active Active
- 2018-01-25 MX MX2019008787A patent/MX2019008787A/en unknown
-
2019
- 2019-07-22 IL IL268221A patent/IL268221B/en unknown
- 2019-07-23 PH PH12019501693A patent/PH12019501693A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN110225908A (en) | 2019-09-10 |
ES2872923T3 (en) | 2021-11-03 |
KR102571911B1 (en) | 2023-08-28 |
MY196680A (en) | 2023-04-29 |
AU2018211801A1 (en) | 2019-08-15 |
TW201833099A (en) | 2018-09-16 |
RU2019123279A3 (en) | 2021-03-31 |
PT3575293T (en) | 2021-05-25 |
JPWO2018139527A1 (en) | 2019-06-27 |
PL3575293T3 (en) | 2021-09-06 |
EP3575293A1 (en) | 2019-12-04 |
US20190389837A1 (en) | 2019-12-26 |
EP3575293A4 (en) | 2019-12-04 |
JP6605763B2 (en) | 2019-11-13 |
HUE054883T2 (en) | 2021-10-28 |
RU2019123279A (en) | 2021-02-26 |
WO2018139527A1 (en) | 2018-08-02 |
MX2019008787A (en) | 2019-09-11 |
IL268221A (en) | 2019-09-26 |
US10836747B2 (en) | 2020-11-17 |
TWI779007B (en) | 2022-10-01 |
AU2018211801B2 (en) | 2021-07-08 |
EP3575293B1 (en) | 2021-03-10 |
WO2018139527A9 (en) | 2018-09-20 |
BR112019015352A2 (en) | 2020-03-10 |
IL268221B (en) | 2022-03-01 |
KR20190111035A (en) | 2019-10-01 |
CA3051605A1 (en) | 2018-08-02 |
PH12019501693A1 (en) | 2020-06-15 |
DK3575293T3 (en) | 2021-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020011528A (en) | Substituted heterocyclic inhibitors of ptpn11. | |
WO2015168466A8 (en) | Inhibitors of lysine specific demethylase-1 | |
PH12017502363A1 (en) | Brk inhibitory compound | |
TN2020000125A1 (en) | Amino-fluoropiperidine derivative as kinase inhibitor | |
MX2019007243A (en) | Ectonucleotidase inhibitors and methods of use thereof. | |
IN2015DN00827A (en) | ||
PH12019501811A1 (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
PH12019501690A1 (en) | Pyrimidine compound and pharmaceutical use thereof | |
SA520412335B1 (en) | Oxy-fluoropiperidine derivatives as kinase inhibitor | |
PH12016501493B1 (en) | Heteroaryl amides as inhibitors of protein aggregation | |
TR201900148T4 (en) | 2,4 diamino-quinoline substituted as novel agents against cancer. | |
PH12016502130A1 (en) | Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect | |
NZ726695A (en) | Gls1 inhibitors for treating disease | |
WO2018183370A3 (en) | Kdm4 inhibitors | |
MX2020000523A (en) | Isochroman compounds and uses thereof. | |
PH12019501693A1 (en) | Ethane-sulfonate salt of quinoline derivative | |
SA520411726B1 (en) | Novel Phenylpyridine Derivative and Pharmaceutical Composition Comprising The Same | |
PH12016502568A1 (en) | Novel heterocyclic compound | |
MX2018002177A (en) | Novel catechol derivative and pharmaceutical composition comprising same. | |
MX2021006490A (en) | Heteroaromatic compounds as vanin inhibitors. | |
AU2018258588A8 (en) | Inhibitors of TRIM33 and methods of use | |
MX2019014436A (en) | Pyridoquinazoline derivatives useful as protein kinase inhibitors. |